Insulin analogues in children and teens with type 1 diabetes: Advantages and caveats

Pediatric Clinics of North America

Volumn 52, Issue 6, 2005, Pages 1651-1675

  Rachmiel, Marianna ^a   Perlman, Kusiel ^a   Daneman, Denis ^a  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACARBOSE; AMYLIN; BIGUANIDE DERIVATIVE; DETEMIR; GLUCAGON LIKE PEPTIDE 1; HUMAN INSULIN; INSULIN; INSULIN ASPART; INSULIN DERIVATIVE; INSULIN GLARGINE; INSULIN LISPRO; INSULIN SENSITIZING AGENT; INSULIN ZINC SUSPENSION; ISOPHANE INSULIN; METFORMIN; PIOGLITAZONE; PIRENZEPINE; PRAMLINTIDE; SOMATOMEDIN C; UNCLASSIFIED DRUG;

BONE TUMOR; BREAST TUMOR; CLINICAL TRIAL; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DRUG EFFICACY; DRUG FORMULATION; FOLLOW UP; GASTROINTESTINAL DISEASE; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; MEDICAL CARE; MEDICAL TECHNOLOGY; OUTCOMES RESEARCH; OVARY TUMOR; RETINOPATHY; REVIEW; RISK ASSESSMENT; SAFETY; SOCIAL PSYCHOLOGY; SOCIOECONOMICS;

ADOLESCENT; AMYLOID; CHILD; DIABETES MELLITUS, TYPE 1; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; METFORMIN;

EID: 27844545747     PISSN: 00313955     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pcl.2005.07.010     Document Type: Review

References (103)

1. R. Tisch, and H. McDevitt Insulin-dependent diabetes mellitus Cell 85 3 1996 291 297
2. The Diabetes Control and Complication Trial Research Group The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus N Engl J Med 329 14 1993 977 986
3. Diabetes Control and Complications Trial Research Group Effect of intensive diabetes treatment on the development and progression of long-term complications in adolescents with insulin-dependent diabetes mellitus: diabetes control and complications trial J Pediatr 125 2 1994 177 188
4. Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group Beneficial effects of intensive therapy of diabetes during adolescence: outcomes after the conclusion of diabetes control and complications trial J Pediatr 139 6 2001 804 812
5. The Diabetes Control and Complication Trial Research Group Hypoglycemia in the diabetes control and complication trial research group Diabetes 46 2 1997 271 286
6. K. Matyka, L. Wigg, and S. Pramming Cognitive function and mood after profound nocturnal hypoglycemia in children with conventional insulin treatment for diabetes Arch Dis Child 81 2 1999 138 142
7. P.A. Porter, G. Byrne, and S. Stick Nocturnal hypoglycemia and sleep disturbances in young teenagers with insulin dependent diabetes mellitus Arch Dis Child 75 2 1996 120 123
8. H.B. Mortensen, and P. Hougaard For the Hvidore study group on childhood diabetes: comparison of metabolic control in a cross sectional study of 2873 children and adolescents with insulin-dependent diabetes from 18 countries Diabetes Care 20 5 1997 714 720
9. M. Bergszaszi, N. Tubiana-Rufi, and K. Benali Nocturnal hypoglycaemia in children and adolescents with insulin dependent diabetes mellitus: prevalence and risk-factors J Pediatr 131 1 1997 27 33
10. C.L. Acerini, T.D. Cheetham, and J.A. Edge Both insulin sensitivity and insulin clearance in children and young adults with type 1(insulin dependent) diabetes vary with growth hormone concentrations and with age Diabetologia 43 1 2000 61 68
11. H.B. Mortensen, K.J. Robertson, and H.J. Aantoot For the Hvidore study group on childhood diabetes: insulin management and metabolic control of type 1diabetes mellitus in children and adolescents in 18 countries Diabet Med 15 9 1998 752 759
12. P. Chase, T. Lockspeiser, and B. Peery The impact of the diabetes control and complications trial and humalog insulin on glycohemoglobin levels and severe hypoglycemia in type 1 diabetes Diabetes Care 24 1 2001 430 434
13. M. Kovacs, S. Jyengar, and D. Goldston Psychological functioning of children with insulin-dependent diabetes mellitus: a longitudinal study J Pediatr Psychol 15 5 1990 619 632
14. S.A. Amiel, R.S. Sherwin, and D.C. Simonson Impaired insulin action in puberty: a contributing factor to poor glycemic control in adolescents with diabetes N Engl J Med 315 4 1986 215 219
15. J.A. Ruggles, D. Kelemen, and A. Baron Emerging therapies: controlling glucose homeostasis, immunotherapy, islet cell transplantation, gene therapy and islet cell neogenesis and regeneration Endocrinol Metab Clin N Am 33 1 2004 239 252
16. International Society for Pediatric and Adolescent Diabetes Consensus Guidelines. The Netherlands: Medical Forum International for the International Society for Pediatric and Adolescent Pediatrics 2000 1
17. B. Zinman The physiological replacement of insulin: an elusive goal N Engl J Med 321 6 1989 363 370
18. G.B. Bolli, and D.R. Owens Insulin glargine Lancet 356 9228 2000 443 445
19. D.R. Owens, B. Zinman, and G.B. Bolli Insulins today and beyond Lancet 358 9283 2001 739 746
20. National Institute for Clinical Excellence Guidance on the use of long acting insulin analogues for the treatment of diabetes-insulin glargine. Technology appraisal guidelines no. 53 2002 National Institute for Clinical Excellence London 1 26
21. R. Almezadeh, J.N. Ellis, and M.K. Holzum Beneficial effects of continuous subcutaneous insulin infusion and flexible multiple daily insulin regimen using insulin glargin in type 1 diabetes Pediatrics 114 11 2004 e91 e95
22. N.A. Reynolds, and A.J. Wagastaff Insulin aspart: a review of its use in the management of type1 and type 2 diabetes mellitus Drugs 64 17 2004 1957 1974
23. S. Gammeltoft, B.F. Hansen, and L. Dideriksen Insulin aspart: a novel rapid acting human insulin analogue Expert Opin Investig Drugs 8 9 1999 1431 1441
24. G.B. Bolli, R.D. Di Marchi, and G.D. Park Insulin analogues and their potential in the management of diabetes mellitus Diabetologia 42 10 1999 1151 1167
25. C. Homko, A. Deluzio, and C. Jimenez Comparison of insulin aspart and lispro: pharmacokinetic and metabolic effects Diabetes Care 26 7 2003 2027 2031
26. S.R. Mudaliar, F.A. Lindberg, and M. Joyce Insulin aspart (B28 Asp-insulin): a fasting acting analog of human insulin. Absorption kinetics and action profile compared with regular human insulin in healthy nondiabetic subjects Diabetes Care 22 9 1999 1501 1506
27. B. Rami, and E. Schober Postprandial glycaemia after regular and lispro insulin in children and adolescents with diabetes Eur J Pediatr 156 11 2000 838 840
28. H. Mortensen, A. Lindholm, and B. Olsen Rapid appearance and onset of action of insulin aspart in paediatric subjects with type 1 diabetes Eur J Pediatr 159 7 2000 483 488
29. D.C. Howey, R.R. Bowsher, and R.L. Brunelle [Lys(B28), Pro(B29)]-human insulin: a rapidly absorbed analogue of human insulin Diabetes 43 3 1994 396 402
30. J.H. DeVries, A. Lindholm, and J.L. Jacobsen The Tri-Continental Insulin Aspart Study Group: a randomized trial of insulin aspart with intensified basal NPH insulin supplementation in people with type 1 diabetes Diabet Med 20 4 2003 312 318
31. P.D. Home, A.L. Lindholm, B. Hylleberg for the UK Insulin Aspart Study Group Improved glycemic control with insulin aspart: a multicenter randomized double blind crossover trial in type 1 diabetes patients Diabetes Care 21 11 1998 1904 1909
32. A. Mohn, K.A. Matyka, and D.A. Harris Lispro or regular insulin for multiple injection therapy in adolescence: difference in free insulin and glucose levels overnight Diabetes Care 22 1 1999 27 32
33. M.E. Ford-Adams, N.P. Murphy, and E.J. Moore Insulin lispro: a potential role in preventing nocturnal hypoglycemia in young children with diabetes mellitus Diabet Med 20 8 2003 656 660
34. T. Danne, J. Aman, E. Schober for the ANA 1200 study group A comparison of postprandial and preprandial administration of insulin aspart in children and adolescents with type 1diabetes Diabetes Care 26 8 2003 2359 2364
35. L.C. Deeb, J.H. Holcombe, and R. Brunelle Insulin lispro lowers postprandial glucose in prepubertal children with diabetes Pediatrics 108 5 2001 1175 1179
36. K.S. Rutledge, H.P. Chase, and G.L. Klingensmith Effectiveness of postprandial humalog in toddlers with diabetes Pediatrics 100 6 1997 968 972
37. P.M. Jehle, C. Micheler, and D.R. Jehle Inadequate suspension of neutral protamine Hagedorn (NPH) insulin in pens Lancet 354 1999 1604 1607
38. M. Lepore, S. Pampanelli, and C. Fanelli Pharmacokinetics and pharmacodynamics of subcutaneous injection of long acting human insulin analog glargine, NPH insulin, and Ultralente human insulin and continuous subcutaneous infusion of insulin lispro Diabetes 49 12 2000 2142 2148
39. H.P. Chase, B. Dixon, and J. Pearson Reduced hypoglycemic episodes and improved glycemic control in children with type 1 diabetes using insulin glargine and neutral protamine hagedorn insulin J Pediatr 143 6 2003 737 740
40. T.M. Chapman, and C.M. Perry Insulin detemir: a review of its use in the management of type 1 and 2 diabetes mellitus Drugs 64 22 2004 2577 2595
41. J. Rosenstock, G. Park, and J. Zimmerman Basal insulin glargine (HOE 901) versus NPH insulin in patients with type1 diabetes on multiple daily insulin regimens Diabetes Care 23 8 2000 1137 1142
42. Y.C. Kudva, A. Basu, and G.D. Jenkins Randomized controlled clinical trial of glargine versus ultralente insulin in the treatment of type 1 diabetes Diabetes Care 28 1 2005 10 14
43. P. Rossetti, S. Pampanelli, and C. Fanelli Intensive replacement of basal insulin in patients with type 1 diabetes given rapid-acting insulin analog at mealtime: a 3 month comparison between administration of NPH insulin four times daily and glargine insulin at dinner or bedtime Diabetes Care 26 5 2003 1490 1496
44. A. Mohn, S. Strang, and K. Wernicke-Panten Nocturnal glucose control and free insulin levels in children with type 1 diabetes by use of the long acting insulin HOE 901 as part of a three injection regimen Diabetes Care 23 4 2000 557 559
45. S.K. Garg, P.A. Gottlieb, and M.E. Hisatomi Improved glycemic control without an increase in severe hypoglycemic episodes in intensively treated patients with type 1 diabetes receiving morning, evening, or split dose insulin glargine Diabetes Res Clin Pract 66 1 2004 49 56
46. A. Hamann, S. Matthaei, C. Rosek for HOE901/4007 study group A randomized clinical trial comparing breakfast, dinner, or bedtime administration of insulin glargine in patients with type 1 diabetes Diabetes Care 26 6 2003 1738 1744
47. E.A. Doyle, S.A. Weinzimer, and A.T. Steffen A randomized, prospective trial comparing the efficacy of continuous subcutaneous insulin infusion with multiple daily injections using glargine Diabetes Care 27 7 2004 1554 1558
48. T. Heise, L. Nosek, and B.B. Ronn Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes Diabetes 53 6 2004 1614 1620
49. T. Danne, K. Lupke, and K. Walte Insulin detemir is characterized by a consistent pharmacokinetic profile across age-groups in children, adolescents, and adults with type 1 diabetes Diabetes Care 26 11 2003 3087 3092
50. K. Hermansen, S. Madsbad, and H. Perrild Comparison of the soluble basal insulin analog insulin detemir with NPH insulin Diabetes Care 24 2 2001 296 301
51. S.S. Jhee, W.H. Lyness, and B. Rojas Similarity of insulin detemir pharmacokinetics, safety, and tolerability profiles in healthy caucasian and Japanese American subjects J Clin Pharmacol 44 3 2004 258 264
52. P. Raskin, L. Klaff, and R. Bergenstal A 16 week comparison of the novel insulin analog insulin glargine (HOE 901) and NPH human insulin used with lispro in patients with type 1 diabetes Diabetes Care 23 11 2000 1666 1671
53. R.E. Ratner, I.B. Hirsh, and J.L. Neifing Less hypoglycemia with insulin glargine in intensive insulin therapy for type 1 diabetes Diabetes Care 23 5 2000 639 643
54. P. Vague, J.L. Selam, and S. Skeie Insulin detemir is associated with more predictable glycemic control and reduced risk of hypoglycemia than NPH insulin in patients with type 1 diabetes on a basal-bolus regimen with premeal insulin aspart Diabetes Care 26 3 2003 590 596
55. T.R. Pieber, I. Eugene-Jorchine, and E. Derobert Efficacy and safety of HOE 901 versus NPH insulin in patients with type 1 diabetes Diabetes Care 23 2 2000 157 162
56. E. Schober, E. Schoenle, and J. Van Dyk The pediatric study group of insulin glargine: comparative trial between insulin glargine and NPH insulin in children and adolescents with type 1 diabetes mellitus J Pediatr Endocrinol Metab 15 4 2002 369 376
57. G. Milazzo, V. Sciacca L' Papa, and I.D. Goldfine AspB10 insulin induction of increased mitogenic responses and phenotypic changes in human breast epithelial cells: evidence for enhanced interactions with the insulin-like growth factor-I receptor Mol Carcinogen 18 1 1997 19 25
58. P. Kurtzhals, L. Schaffer, and A. Sorensen Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogues designed for clinical use Diabetes 49 6 2000 999 1005
59. L. Berti, M. Kellerer, and B. Bossenmaier The long acting human insulin analogue HOE 901: characteristics of insulin signaling in comparison to Asp (B10) and regular insulin Horm Metab Res 30 3 1998 123 129
60. B23] insulin (HOE 901) in muscle cells Eur J Pharmacol 320 2 1997 259 265
61. A. Siebenhofer, J. Plank, and A. Berghold Short acting insulin analogues versus regular insulin in patients with diabetes mellitus Cochrane Database of Systemic Reviews 3 2004
62. A. Seibenhofer, J. Plank, and A. Berghold Meta-analysis of short-acting insulin analogues in adult patients with type 1 diabetes: continuous subcutaneous insulin infusion versus injection therapy Diabetologia 47 11 2004 1895 1905
63. S.K. Garg, J.A. Carmain, and K.C. Braddy Pre-meal insulin analogue insulin lispro vs humulin R insulin treatment in youth subjects with type 1 diabetes Diabet Med 13 1 1996 47 52
64. H. Lunt, D. Kendali, and M.P. Moore Prospective audit of conversion from regular to lispro insulin during routine clinical care Int Med J 34 2004 320 323
65. S. Tupola, J. Komulainen, and J. Jaaskelainen Post-prandial insulin lispro vs. human regular insulin in prepubertal children with type 1 diabetes mellitus Diabet Med 18 2001 654 658
66. P.D. Home, A. Lindholm, A. Riis for the European Insulin Aspart Study Group Insulin aspart vs. human insulin in the management of long term blood glucose control in type 1 diabetes mellitus: a randomized controlled trial Diabet Med 17 11 2000 762 771
67. G. Schernthaner, W. Wein, and K. Sanndholzer Postprandial insulin lispro: a new therapeutic option for type 1 diabetic patients Diabetes Care 21 4 1998 570 573
68. S. Pampanelli, E. Torlone, and C. Lalli Improved postprandial metabolic control after subcutaneous injection of a short-acting insulin analogue in IDDM of short duration with residual pancreatic β-cell function Diabetes Care 18 11 1995 1452 1459
69. R.L. Brunelle, J. Llewellyn, and J.H. Anderson Jr Meta-analysis of the effect of insulin lispro on severe hypoglycemia in patients with type 1 diabetes Diabetes Care 21 10 1998 1726 1731
70. P. Raskin, R.A. Guthrie, and L. Leiter Use of insulin aspart, a fast acting insulin analogue, as the mealtime insulin in the management of patients with type 1 diabetes Diabetes Care 23 5 2000 105 114
71. G. Tamas, M. Marre, and R. Astotga Glycaemic control in type 1 diabetic patients using optimised insulin aspart or human insulin in a randomized multinational study Diabetes Res Clin Pract 54 2 2001 105 114
72. E. Tsalikian Insulin aspart in pediatric and adolescent patients with type 1 diabetes [abstract 767] Diabetologia 43 1 2000 200
73. J.H. Holcombe, S. Zalani, V.K. Arora for the Lispro in Adolescents Study Group Comparison of insulin lispro with regular human insulin for the treatment of type 1 diabetes in adolescents Clin Ther 24 4 2002 629 638
74. J.M. Fairchild, G.R. Ambler, and C.H. Genoud-Lowton Insulin lispro versus regular insulin in children with type 1 diabetes on twice daily insulin Pediatric Diabetes 1 3 2000 135 141
75. F. Porcellati, P. Rossetti, and S. Pampanelli Better long term glycemic control with the basal insulin glargine as compared with NPH in patients with type 1 diabetes mellitus given meal time lispro insulin Diabet Med 21 11 2004 1213 1220
76. P. Home, P. Bartley, D. Russel Jones for the Study to Evaluate the Administration of Detemir Insulin Efficacy, Safety and Suitability (STEADINESS) Study Group Insulin detemir offers improved glycemic control compared with NPH insulin in people with type 1 diabetes Diabetes Care 27 5 2004 1081 1087
77. I. De Leeuw, P. Vague, and J.L. Selam Diabetes, insulin detemir used in basal-bolus therapy in people with type 1 diabetes is associated with a lower risk of nocturnal hypoglycaemia and less weight gain over 12 months in comparison to NPH insulin Diabetes Obes Metabolism 7 1 2005 73 82
78. A. Roberts, E. Standl, and T. Bayer Efficacy and safety of 6 months treatment with insulin detemir in type 1 diabetic patients on a basal-bolus regimen [abstract 795 plus poster] Diabetologia 44S1 2001 207
79. K. Hermansen, P. Fontaine, and K.K. Kukolja Insulin analogues (insulin detemir and insulin aspart) versus traditional human insulins (NPH insulin and regular human insulin) in basal-bolus therapy for patients with type 1 diabetes Diabetologia 47 4 2004 622 629
80. E. Standl, H. Lang, and A. Roberts The 12-month efficacy and safety of insulin detemir and NPH insulin in basal-bolus therapy for the treatment of type 1 diabetes Diabetes Technol Ther 6 5 2004 579 588
81. A. Fritsche, and H. Haring At last, a weight neutral insulin? Int J Obes Relat Metab Disord 28 Suppl 2 2004 S41 S46
82. N.P. Murphy, S.M. Keane, and K.K. Ong Randomized cross-over trial of insulin glargine plus lispro or NPH insulin plus regular human insulin in adolescents with type 1 diabetes on intensive insulin regimen Diabetes Care 26 3 2003 799 804
83. R. Schiaffini, P. Ciampalini, and S. Spera An observational study comparing continuous subcutaneous insulin infusion (CSII) and insulin glargin in children with T1DM Diabetes Metab Res Rev 21 2005 347 352
84. K. Robertson, E. Schonle, and Z. Gucev Benefits of insulin detemir over NPH insulin in children and adolescents with type 1 diabetes: lower and more predictable fasting plasma glucose and lower risk nocturnal hypoglycemia [abstract and poster] Diabetes 53 Suppl 2 2004 A144
85. P. Royle, N. Waugh, and L. McAuley Inhaled insulin in diabetes mellitus Cochrane Database of Systematic Reviews 3 2004 CD003890
86. T. Quattrin, A. Belanger, N.J. Bohannon Exubera Phase III Study Group Efficacy and safety of inhaled insulin (Exubera) compared with subcutaneous insulin therapy in patients with type 1 diabetes: results of a 6-month, randomized, comparative trial Diabetes Care 27 11 2004 2622 2627
87. W.V. Tamborlane, W. Bonfig, and E. Boland Recent advances in treatment of youth with type 1 diabetes: better care through technology Diabet Med 18 11 2001 864 870
88. C.A. Jefferies, J. Hamilton, and D. Daneman Potential adjunctive therapies in adolescents with type 1 diabetes mellitus Treat Endocrinol 3 5 2004 337 343
89. J. Hamilton, E. Cummings, and V. Zdravkovik Metformin as an adjuvant therapy in adolescents with type 1 diabetes and insulin resistance: randomized controlled trial Diabetes Care 26 1 2003 138 143
90. B. Sarnblad, M. Kroon, and J. Aman Metformin as additional therapy in adolescents with poorly controlled type 1 diabetes: randomized placebo-controlled trial with aspects on insulin sensitivity Eur J Endocrinol 149 4 2003 323 329
91. V. Zdravkovic, J. Hamilton, and D. Daneman Pioglitazone as adjunctive therapy in adolescents with type 1 diabetes and insulin resistance Diabetes 54 Suppl 2005 A452
92. G. Dimitriadis, C. Karaiskos, and S. Raptis Effects of prolonged (6 months) alpha-glucosidase inhibition on blood glucose control and insulin requirements in patients with insulin-dependent diabetes mellitus Horm Metab Res 18 4 1986 253 255
93. G. Riccardi, R. Giacco, and M. Parillo Efficacy and safety of acarbose in the treatment of type 1 diabetes mellitus: a placebo-controlled, double blind, multicenter study Diabet Med 16 3 1999 228 232
94. P. Hollander, X. Pi-Sunyer, and R.F. Coniff Acarbose in the treatment of type 1 diabetes Diabet Care 20 3 1997 248 253
95. J.P. Sels, H.E. Verdonk, and B.H. Wolffenbuttel Effects of acarbose (Glucobay) in persons with type 1 diabetes: a multicenter study Diab Res Clin Pract 41 2 1998 139 145
96. S.V. Efelman, and C. Weyer Unresolved challenges with insulin therapy in type 1 and type 2 diabetes: potential benefit of replacing amylin, a second β cell hormone Diabetes Technol Ther 4 2 2002 175 189
97. F. Whitehouse, D.F. Kruger, and M. Fineman A randomized study and open-label extension evaluating the long term efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetes Diabetes Care 25 4 2002 724 730
98. A. Gottlieb, M. Velte, and M. Fineman Pramlintide as an adjunct to insulin therapy improved glycemic and weight control in people with type 1 diabetes during treatment for 52 weeks Diabetes 49 2000 A109
99. R.A. Heptulla, L.M. Rodriguez, and L. Bomgaars The role of amylin and glucagons in the dampening of glycemic excursions in children with type 1 diabetes Diabetes 54 4 2005 1100 1107
100. D.J. Drucker, and L. Miniriview The glucagon-like peptides Endocrinology 142 2 2001 521 527
101. J. Dupre, M.T. Behme, and T.J. McDonald Exendin-4 normalized postcibal glycemic excursions in type 1 diabetes J Clin Endocrinol Metab 89 7 2004 3469 3473
102. J. Dupre, M.T. Behme, and I.M. Hramiak Subcutaneous glucagon-like peptide 1 combined with insulin normalizes postcibal glycemic excursions in IDDM Diabetes Care 20 3 1997 381 384
103. J. Dupre, M.T. Behme, and I.M. Hramiak Glucagon-like peptide I reduces postprandial glycemic excursions in IDDM Diabetes 44 6 1995 626 630